Clinical trial
Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
NCT00304096 · University of Virginia, Other · Completed
Key facts
| NCT number | NCT00304096 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer |
| Official title | Evaluation of the Safety and Immunogenicity of Vaccination With Multiple Synthetic Peptides in Participants With Advanced Breast Cancer |
| Lead sponsor | University of Virginia, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological |
| Interventions | synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine |
| Enrollment | 12 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Apr 1, 2008 |
| First posted | Mar 17, 2006 |
| Last update posted | Apr 9, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: